• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SUMATRIPTAN Drug Record

  • Summary
  • Interactions
  • Claims
  • SUMATRIPTAN chembl:CHEMBL128 Approved

    Alternate Names:

    SUMATRIPTAN
    TOSYMRA
    N02CC01
    IMITREX
    1-[3-(2-DIMETHYLAMINOETHYL)-1H-INDOL-5-YL]-N-METHYL-METHANESULFONAMIDE
    3-[2-(DIMETHYLAMINO)ETHYL]-N-METHYLINDOLE-5-METHANESULFONAMIDE
    (3-[2-(DIMETHYLAMINO)ETHYL]-1H-INDOL-5-YL)-N-METHYLMETHANESULFONAMIDE
    IMIGRAN®
    TRIPTAN
    SUMATRIPTÁN
    SUMATRAN
    SUMATRIPTAN SUCCINATE
    SUMATRIPTANUM
    3-(2-(DIMETHYLAMINO)ETHYL)-N-METHYL-1H-INDOLE-5-METHANESULFONAMIDE
    SUMAX
    NP101
    GR-43175C
    chembl:CHEMBL128
    pubchem.compound:5358
    chemidplus:103628-46-2
    rxcui:37418
    drugbank:00669

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antimigraine agent
    Drug Class anti-migraine agents
    Year of Approval 1992
    (4 More Sources)

    Publications:

    Mitsikostas et al., 2002, 5-Hydroxytryptamine(1B/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis., Cephalalgia
    Roy et al., 2000, Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves., J. Heart Valve Dis.
    Mitsikostas et al., 1999, Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis., Eur. J. Pharmacol.
    Nikai et al., 2008, Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan., Pain
    Zohar et al., 2004, Serotonin-1D hypothesis of obsessive-compulsive disorder: an update., J Clin Psychiatry
    Razzaque et al., 2002, 5-HT1B-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan., Br J Clin Pharmacol
    Baxter, 2001, Brain mediation of Anolis social dominance displays. III. Differential forebrain 3H-sumatriptan binding in dominant vs. submissive males., Brain Behav. Evol.
    Akin et al., 2002, Involvement of 5-HT1B and 5-HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery., Br. J. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Koran et al., 2001, Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder., Eur Neuropsychopharmacol
    Cohen et al., 1999, 5-Hydroxytryptamine(1A) receptor activation enhances norepinephrine release from nerves in the rabbit saphenous vein., J. Pharmacol. Exp. Ther.
    Johnson et al., 2001, Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain., Eur. J. Pharmacol.
    Pauwels et al., Present and future of 5-HT receptor agonists as antimigraine drugs., Clin Neuropharmacol
    Janssen et al., 2004, Influence of 5-HT1 receptor agonists on feline stomach relaxation., Eur. J. Pharmacol.
    Cohen et al., 2000, Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha)., Br. J. Pharmacol.
    Razzaque et al., 1999, Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation., Br J Clin Pharmacol
    Cargnin S et al., 2014, Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache., Eur J Clin Pharmacol
    Grånäs et al., 1999, Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor., Eur. J. Pharmacol.
    Cohen et al., 1999, Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization., J. Cereb. Blood Flow Metab.
    Dupuis et al., 1999, Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPgammaS binding responses., Brain Res. Mol. Brain Res.
    Schürks M et al., 2007, G protein beta3 polymorphism and triptan response in cluster headache., Clin Pharmacol Ther
    Coulie et al., 1998, 5-Hydroxytryptamine-1 receptor activation inhibits endocrine pancreatic secretion in humans., Am. J. Physiol.
    Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem
  • SUMATRIPTAN   HTR1F

    Interaction Score: 6.31

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name sumatriptan,Imitrex
    Novel drug target Established target
    Trial Name MT 400,Treximet

    PMIDs:
    12110114 10225363 10367177 15178373 18723285 11752352 11015308 10073743


    Sources:
    TdgClinicalTrial TEND

  • SUMATRIPTAN   HTR1D

    Interaction Score: 2.88

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Serotonin 1d (5-HT1d) receptor agonist
    Direct Interaction yes
    Trial Name MT 400,Treximet

    PMIDs:
    12110114 10772044 10225363 18723285 15554784 11874390 11641558 12010765 11752352 11313163 10454495


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • SUMATRIPTAN   HTR1B

    Interaction Score: 1.87

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name MT 400,Treximet
    Novel drug target Established target
    Trial Name NP101,Zelrix

    PMIDs:
    10513577 10772044 10225363 18723285 11874390 10458598 12010765 12110114 11752352 10454495 10101238


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • SUMATRIPTAN   DBH

    Interaction Score: 1.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25096645


    Sources:
    PharmGKB

  • SUMATRIPTAN   AQP4

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18572411


    Sources:
    DTC

  • SUMATRIPTAN   GNB3

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17361120


    Sources:
    PharmGKB

  • SUMATRIPTAN   GCG

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9486164


    Sources:
    NCI

  • SUMATRIPTAN   COMT

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25096645


    Sources:
    PharmGKB

  • SUMATRIPTAN   HTR2B

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • SUMATRIPTAN   HTR1A

    Interaction Score: 0.16

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name MT 400,Treximet
    Novel drug target Established target
    Trial Name NP101,Zelrix

    PMIDs:
    11513839


    Sources:
    TdgClinicalTrial

  • SUMATRIPTAN   BDNF

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25096645


    Sources:
    PharmGKB

  • SUMATRIPTAN   HTR2A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25096645


    Sources:
    PharmGKB

  • SUMATRIPTAN   OPRM1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25096645


    Sources:
    PharmGKB

  • SUMATRIPTAN   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25096645


    Sources:
    PharmGKB

  • TEND: SUMATRIPTAN

    • Version: 01-August-2011

    Alternate Names:
    SUMATRIPTAN Primary Drug Name

    Drug Info:
    Year of Approval 1992
    Drug Class anti-migraine agents

    Publications:

  • TdgClinicalTrial: SUMATRIPTAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antimigraine agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: SUMATRIPTAN

    • Version: 14-September-2017

    Alternate Names:
    C1240 NCI drug code

    Drug Info:

    Publications:
    Coulie et al., 1998, 5-Hydroxytryptamine-1 receptor activation inhibits endocrine pancreatic secretion in humans., Am. J. Physiol.

  • DTC: SUMATRIPTAN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL128 ChEMBL Drug ID

    Drug Info:

    Publications:
    Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem

  • PharmGKB: sumatriptan

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Cargnin S et al., 2014, Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache., Eur J Clin Pharmacol
    Schürks M et al., 2007, G protein beta3 polymorphism and triptan response in cluster headache., Clin Pharmacol Ther

  • TTD: Sumatriptan

    • Version: 2020.06.01

    Alternate Names:
    D0Z6UC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL128

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL128

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21